Li C, Zhang Q, Zhang S, et al. Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review. BMC Cancer. 2019;19(1):217. https://doi.org/10.1186/s12885-019-5393-y.

Article  PubMed  PubMed Central  Google Scholar 

Hackethal A, Brueggmann D, Bohlmann MK, Franke FE, Tinneberg HR, Münstedt K. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data [published correction appears in Lancet Oncol. 2009 May;10(5):446]. Lancet Oncol. 2008; 12 (9), 1173–1180. https://doi.org/10.1016/S1470-2045(08)70306-1

Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022;126:1663–75. https://doi.org/10.1038/s41416-022-01743-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen RJ, Chen KY, Chang TC, et al. Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary. J Formos Med Assoc. 2008;107(11):857–68. https://doi.org/10.1016/s0929-6646(08)60202-8.

Article  PubMed  Google Scholar 

Yoshimura K, Yamanoi K, Kanai M, et al. Nivolumab for malignant transformation of ovarian mature cystic teratoma. Gynecol Oncol Rep. 2022;10(44):101115. https://doi.org/10.1016/j.gore.2022.101115.

Article  Google Scholar 

Zhang C, Ma T. Poorer prognosis of ovarian squamous cell carcinoma than serous carcinoma: a propensity score matching analysis based on the SEER database. J Ovarian Res. 2020;13(1):75. https://doi.org/10.1186/s13048-020-00675-y.

Article  PubMed  PubMed Central  Google Scholar 

Park JW, Bae JW. Pure primary ovarian squamous cell carcinoma: a case report and review of the literature. Oncol Lett. 2015;9(1):321–3.

Article  PubMed  Google Scholar 

Koufopoulos N, Nasi D, Goudeli C, et al. Primary squamous cell carcinoma of the ovary. Review of the literature J Buon. 2019;24(5):1776–84.

PubMed  Google Scholar 

Glasspool RM, Gonzalez MA, Millan D, et al. Gynecologic cancer intergroup (GCIG) consensus review for squamous cell carcinoma of the ovary. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S26–9.

Article  PubMed  Google Scholar 

Xu Y, Li L. Primary squamous cell carcinoma arising from endometriosis of the ovary: a case report and literature review. Curr Probl Cancer. 2018;42(3):329–36.

Article  PubMed  Google Scholar 

Wu SY, Giannini A, Girardo M, Schmitt A, Magrina JF, Butler K. Malignant transformation of squamous cell carcinoma in mature cystic teratoma of the ovary: a systematic review and meta-analysis of data. Gynecol Obstet Invest. 2024;19:1–13. https://doi.org/10.1159/000542672.

Article  Google Scholar 

Wu M, Bennett JA, Reid P, Fleming GF, Kurnit KC. Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab. Gynecol Oncol Rep. 2021;22(37):100837. https://doi.org/10.1016/j.gore.2021.100837.

Article  Google Scholar 

Song XC, Wang YX, Yu M, et al. Case report: management of recurrent ovarian squamous cell carcinoma with PD-1 inhibitor. Front Oncol. 2022;12:789228.

Article  PubMed  PubMed Central  Google Scholar 

Edwards CC, Holloway SB, Sethi S, Lea JS. Role for immunotherapy in pretreated, recurrent, metastatic squamous cell carcinoma arising from mature cystic teratoma. Gynecol Oncol Rep. 2023;6(47):101181. https://doi.org/10.1016/j.gore.2023.101181.

Article  Google Scholar 

Tamura R, Yoshihara K, Nakaoka H, et al. XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary. Oncogene. 2020;39(17):3541–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooke SL, Ennis D, Evers L, et al. The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clin Cancer Res. 2017;23:7633–40. https://doi.org/10.1158/1078-0432.CCR-17-1789.

Article  CAS  PubMed  Google Scholar 

Yoshida K, Yokoi A, Kagawa T, et al. Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. Carcinogenesis. 2019;40(12):1435–44. https://doi.org/10.1093/carcin/bgz135.

Article  CAS  PubMed  Google Scholar 

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348:69–74.The overall mutational burden of SCC arising from MCT is high, it shares similar mutation profiles to SCC.

McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer. JAMA Oncol. 2016;2:46–54. https://doi.org/10.1001/jamaoncol.2015.3638.

Article  PubMed  PubMed Central  Google Scholar 

Ilie M, Bence C, Butori C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2015. https://doi.org/10.1093/annonc/mdv489.

Article  PubMed  Google Scholar 

Gagné A, Wang E, Bastien N, Orain M, et al. Impact of specimen characteristics on PD-L1 testing in non–small cell lung cancer: validation of the IASLC PD-L1 testing recommendations. J Thorac Oncol. 2019;14:2062–70. https://doi.org/10.1016/j.jtho.2019.08.2503.

Article  CAS  PubMed  Google Scholar 

Brunnström H, Johansson A, Westbom-Fremer S, et al. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Mod Pathol. 2017;30:1411–21. https://doi.org/10.1038/modpathol.2017.59.

Article  CAS  PubMed  Google Scholar 

Hong L, Dibaj S, Negrao MV, et al. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC). J Clin Oncol. 2019. https://doi.org/10.1200/JCO.2019.37.

Article  PubMed  PubMed Central  Google Scholar 

Xu H, Lin G, Huang C, et al. Assessment of concordance between 22C3 and SP142 immunohistochemistry assays regarding PD-L1 expression in non-small cell lung cancer. Sci Rep. 2017;7:16956.

Article  PubMed  PubMed Central  Google Scholar 

Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3:1051–8.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Tang X, Zhuo W. Malignant transformation of ovarian teratoma responded well to immunotherapy after failed chemotherapy: a case report. Ann Palliat Med. 2021;10(7):8499–505. https://doi.org/10.21037/apm-20-2429.

Article  PubMed  Google Scholar 

Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019;4:e126908.

Article  PubMed  PubMed Central  Google Scholar